New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity
作者:Dong-Jin Hwang、Yali He、Suriyan Ponnusamy、Michael L. Mohler、Thirumagal Thiyagarajan、Iain J. McEwan、Ramesh Narayanan、Duane D. Miller
DOI:10.1021/acs.jmedchem.8b00973
日期:2019.1.24
propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and
在寻找晚期前列腺癌(PCs)的小分子治疗方法的过程中,发现了一系列新颖的吲哚基和吲哚基丙酰胺(II和III系列)作为选择性雄激素受体降解剂(SARDs)。对雄激素受体(AR)拮抗剂(1)和激动剂(2)丙酰胺的初步研究产生了具有新型SARD活性但代谢稳定性较差的叔苯胺(3)。环化至II和III产生亚微摩尔的AR拮抗作用,并对AR和AR剪接变体(AR SV)产生选择性的蛋白质降解。二和三维持对enzalutamide耐药(Enz-R)突变的ARs和PC细胞的效力,并且对Enz-R异种移植物有效,表明它们具有治疗晚期PCs的潜力。新型SARD的设计,合成和生物学活性,可潜在地用于治疗各种PC,包括去势抵抗性,Enz-R和/或AR SV依赖性的晚期PC,这些已知PC通常无法用已知的激素疗法治疗讨论。